[ORGANIZATION]
Certara
Featured in 2 tracked stories · first seen
Situations
Cerus Corp earnings and product outlook
2 clusters · 5 sources · last updated
Latest: Sarepta Therapeutics Reports Q2 Revenue Decline and Revised Outlook
Cerus Corporation reported second‑quarter 2026 results that met analysts' expectations, posting earnings per share of $0.01 on revenue of $63.3 million. Product revenue rose 10% to $57.4 million, driving a 16% year‑over‑
Also covered in
-
Drug Interaction Database tools support clinical development workflows
[HEALTH] · 2 sources ·